New 'Smart' immune cells take on kidney cancer in early trial

NCT ID NCT07564232

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 5 times

Summary

This early-phase trial is testing a new treatment called LNK001 for people with advanced or metastatic clear cell renal cell carcinoma (a type of kidney cancer) that has not responded to standard treatments. LNK001 is a type of immunotherapy where a patient's own immune cells are modified to better recognize and attack cancer cells. The study will first find the safest dose and then see if it can help control the disease in 40 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LNK001 (a type of CAR T cell therapy that targets two proteins on cancer cells)
What this could lead to: If it works, this could provide a new treatment option for advanced kidney cancer that has stopped responding to standard therapies.
What could go wrong: This is an early phase 1 trial with only 40 participants, so it may not work or could have serious side effects. CAR T therapy can cause severe immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nonpapillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLEAR CELL RENAL CELL CARCINOMA

Contacts and locations

Locations

UT MD Anderson
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.